Circulating Procoagulant Microparticles with Coagulation Factors IXa and XIa Cooperatively Induce Spontaneous Clotting in Plasmas of Patients with Hematological Disorders
Authors: Lipets Elena N. , Vlasova Olga , Urnova Evdokiya , Margolin Oleg , Soloveva Anna , Ataullakhanov Fazoil I , Panteleev Mikhail A. 
Published: October 2019

Abstract 3402

Background & Objective.

Although blood of patients with hematological disorders is known to contain procoagulant material (activated clotting factors, tissue factor, microparticles), its functional significance is poorly understood. Using an in vitro experimental model of immobilized tissue factor-initiated clot growth in platelet-free plasma, we observed formation of activation-surface-independent isolated “spontaneous” clots (SC) throughout the plasma volume in patients with various disorders. The aim of this work was to identify the mechanisms of SC formation.

Methods.

Platelet-free plasma was prepared from citrated whole blood collected by venipuncture. It was supplemented with corn trypsin inhibitor (CTI), recalcified, placed into a thin flat chamber and brought into contact with a surface covered by immobilized tissue factor. Fibrin clot formation as a function of space and time was determined by imaging light scattering. with a CCD camera1 in a thrombodynamics analyzer device (Hemacore LLC, Moscow, Russia). Flow cytometry was used to monitor annexin V-labeled microparticles and platelets in plasma.

Results.

SC were reproducibly observed in plasmas of patients with various disoders including: 4 of 32 patients with ischemic cardiomyopathy, 11 of 29 patients with lymphogranulomatosis during chemotherary, 2 of 5 patients with acute leukemia. SC also appeared in 2 of 36 healthy donor plasmas.

To determine contribution of intrinsic and extrinsic coagulation activation pathways, we blocked them with corn trypsin inhibitor (CTI) and active site-inhibited recombinant factor VIIa, respectively. Tissue factor-dependent activation was essential in 1 of 10 patients tested in this way. CTI inhibited SC in all samples, but never completely (Fig. 1).

To test whether circulating active factors can induce SC, we supplemented normal plasma with factors Va, VIIa, IXa, or XIa known to have long lifetimes (more than 30 min). Addition of factors Va and VIIa led to uniform coagulation thoughout the plasma volume, which did not resemble typical SC patterns observed in the patient plasma (Fig. 2). In contrast, factors IXa and XIa induced isolated clotting centers very similar to those observed in the clinical samples.

SC both in patient plasma and in normal plasma supplemented with factors IXa and XIa disappeared after centrifugation for 30 min at 16000 g, indicating also a contribution of microparticles. This was confirmed by inductions of SC in the bottom layers of normal plasma subjected to identical centrifugation. After phospholipid supplementation, SC reappeared in normal plasma supplemented with factors IXa or XIa, as well as in 3 out of 11 patient plasmas. Flow cytometry revealed an increase in procoagulant microparticles in patient plasmas with SC.

Conclusions.

Here we report observation of a SC phenomenon in vitro in plasma of hematology patients. Although its mechanisms are likely to be different in different illnesses, our data suggest that combination of circulating active factors (specifically, factors IXa and XIa) with circulating procoagulant microparticles is the predominant one. Possible association between the presence of spontaneous clots and clinical manifestations require further study, but prevalence of this phenomenon in the patient plasma indicates possible applicability in diagnostics and.

Disclosures:

Lipets: HemaCore LLC: Employment. Ataullakhanov:HemaCore LLC: Employment, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties. Panteleev:HemaCore LLC: Employment, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.